Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) EPS (Basic) : $-2.76 (TTM As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals EPS (Basic)?

Arrowhead Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-1.24. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.76.

Arrowhead Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2023 was $-1.24. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.77.

Arrowhead Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-1.24. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -2.77.

During the past 3 years, the average EPS without NRI Growth Rate was -31.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Arrowhead Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 79.10% per year. The lowest was -163.00% per year. And the median was 4.50% per year.

Arrowhead Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Arrowhead Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals EPS (Basic) Chart

Arrowhead Pharmaceuticals Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EPS (Basic)

Get a 7-Day Free Trial

0.72

-0.84

-1.36

-1.67

-1.92

Arrowhead Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.39	0.46	-0.96	-1.02	-1.24

Arrowhead Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Arrowhead Pharmaceuticals's Basic EPS for the fiscal year that ended in Sep. 2023 is calculated as

Basic EPS (A: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-205.275	-	0)	/	106.750
	=	-1.92

Arrowhead Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-132.864	-	0)	/	107.415
	=	-1.24

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.76

Arrowhead Pharmaceuticals (NAS:ARWR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Arrowhead Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

HDP1:Germany

Address

177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105

Website

https://www.arrowheadpharma.com

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Executives

James C Hamilton	other: Senior Vice President	177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mauro Ferrari	director	201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Tracie Oliver	officer: Chief Commercial Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Patrick O'brien	officer: General Counsel	225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San	officer: Chief Medical Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Kenneth Allen Myszkowski	officer: CFO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone	director, officer: President and CEO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry	director	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105